Ronald Marcus Net Worth

What's Ronald Marcus's mailing address?

Ronald's mailing address filed with the SEC is 400 E. PRATT STREET, SUITE 606, , BALTIMORE, MD, 21202.

Insiders trading at Cerecor Inc

Over the last 9 years, insiders at Cerecor Inc have traded over $0 worth of Cerecor Inc stock and bought 18,463,844 units worth $43,946,959 . The most active insiders traders include Forest Baskett, Scott D Sandell и Capital, Llc Armistice Capi.... On average, Cerecor Inc executives and independent directors trade stock every 19 days with the average trade being worth of $601,142. The most recent stock trade was executed by Capital, Llc Armistice Capi... on 16 August 2021, trading 50,000 units of CERC stock currently worth $138,000.

What does Cerecor Inc do?

Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803, which are in development for congenital disorders of glycosylation and CERC-006, an oral mTORc1/c2 inhibitor in development for the treatment of complex lymphatic malformations. The company is also developing two monoclonal antibodies, CERC-002, and CERC-007. CERC-002 targets the cytokine LIGHT (TNFSF14) and is in clinical development for treatment of severe pediatric-onset Crohn's disease, and COVID-19 acute respiratory distress syndrome. CERC-007 targets the cytokine IL-18 and is in clinical development for the treatment of Still's disease (adult onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA)), and multiple myeloma (MM). CERC-006, 801, 802 and 803 have all received Orphan Drug Designation and Rare Pediatric Disease Designation, which makes all four eligible for a priority review voucher upon FDA approval.

Cerecor Inc executives and stock owners

Cerecor Inc executives and other stock owners filed with the SEC include:

• Joseph Miller,
  Director
• Jamie Harrell,
  Chief Commercial Officer
• Phil Gutry,
  Independent Director
• Magnus Persson,
  Independent Director
• Gilla Kaplan,
  Independent Director
• Steven Boyd,
  Independent Director
• Suzanne Bruhn,
  Director
• Jeff Wilkins,
  Chief Development Officer
• Garry Neil,
  Chief Scientific Officer
• Christopher Sullivan,
  Interim Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
• Michael Cola,
  Chief Executive Officer, Director
• Sol Barer,
  Chairman of the Board
• Thomas H Aasen,
  Director
• Mariam E Morris,
  Chief Financial Officer
• Ronald Marcus,
  Chief Medical Officer
• John Joseph Kaiser,
  Chief Business Officer
• Eugene A Bauer,
  Director
• Robert Jr. Moscato,
  Director
• Peter Greenleaf,
  Director
• Keith Schmidt,
  Director
• Pericles Calias,
  Chief Scientific Officer
• Matthew V Phillips,
  Chief Commercial Officer
• Randal Jones,
  Director
• Patrick J Crutcher,
  VP, Business Development
• Robert Jr.Lrs International...,
  
• Randal Fremantle, Llc Jones,
  
• Capital, Llc Boyd Steven Ar...,
  
• Simon Pedder,
  Executive Chairman of the Bd
• Uli Hacksell,
  Director
• Tree Partners Iv, L.P.Atp I...,
  
• David M Mott,
  10% owner
• Behshad Sheldon,
  Director
• Anthony A. Jr. Florence,
  10% owner
• Krishna Kittu Kolluri,
  10% owner
• Peter W. Sonsini,
  10% owner
• Harry R Weller,
  10% owner
• Blake M Paterson,
  CEO and President
• Forest Baskett,
  10% owner
• Ravi Viswanathan,
  10% owner
• M James Barrett,
  10% owner
• Scott D Sandell,
  10% owner
• Enterprise Associates 14, L...,
  
• Bioventures V, L.P.Mpm Asse...,
  
• Peter J Barris,
  10% owner
• Patrick J Kerins,
  10% owner
• Isaac Blech,
  Director
• James Archie Jr Harrell,
  Chief Commercial Officer
• Schond L. Greenway,
  CFO